Welcome to our dedicated page for Bioxcel Therapeutics news (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on Bioxcel Therapeutics stock.
BioXcel Therapeutics, Inc. (BTAI) is a clinical-stage biopharmaceutical company pioneering AI-driven drug re-innovation in neuroscience and immuno-oncology. This page serves as the definitive source for official updates including clinical trial progress, regulatory milestones, and strategic initiatives.
Investors and industry observers will find curated press releases detailing advancements in BXCL501 development for neuropsychiatric conditions, immuno-oncology research through subsidiary OnkosXcel, and financial disclosures. Our news collection enables stakeholders to track how machine learning accelerates therapeutic discovery while managing development risks.
Content is organized to highlight essential updates: clinical trial results, regulatory filings, research collaborations, and financial performance. Each update reflects BioXcel's unique approach combining big data analytics with established clinical science to address unmet medical needs.
Bookmark this page for direct access to verified information about BioXcel's innovative pipeline and corporate developments. Check regularly for updates on how artificial intelligence continues to reshape therapeutic discovery in high-need medical specialties.
BioXcel Therapeutics (Nasdaq: BTAI), a biopharmaceutical company focused on AI-driven medicine development in neuroscience and immuno-oncology, has announced its plan to release second quarter 2024 financial results on August 6, 2024, before U.S. financial markets open. The company will host a conference call and webcast at 8:00 AM ET on the same day to discuss the results and provide a business update.
Investors and interested parties can access the webcast link under the 'News/Events' section of BioXcel's website. For those unable to attend live, a replay will be available for 90 days following the event. This announcement highlights BioXcel's commitment to transparency and shareholder communication.
BioXcel Therapeutics (Nasdaq: BTAI) reported preliminary estimated unaudited net revenue of approximately $1.1 million from sales of IGALMI™ (dexmedetomidine) sublingual film for Q2 2024. This represents a 90% increase from the previous quarter and a 141% increase from Q2 2023. The growth was driven by increased contracting with psychiatric care clinics and behavioral health facilities using a small commercial team.
CEO Vimal Mehta expressed satisfaction with the positive feedback received from physicians, caregivers, and patients about IGALMI™ for acute agitation treatment in schizophrenia or bipolar disorders. The company's focused market-access strategy aims to build IGALMI brand equity in the institutional setting, with potential expansion into the at-home market pending successful development and approval of BXCL501.
BioXcel Therapeutics has announced positive topline results from a post-marketing requirement study on IGALMI™ (dexmedetomidine) sublingual film for treating agitation in bipolar disorder or schizophrenia. The study observed no signs of tachyphylaxis, tolerance, or withdrawal at the 180 mcg dose over seven days. All 28 inpatient participants, who experienced agitation episodes, showed symptom improvement as per the Positive and Negative Syndrome Scale-Excitatory Component (PEC) and the Clinical Global Impressions – Improvement (CGI-I) Scale. The 180 mcg dose was well-tolerated, with no serious adverse events reported. These findings support the ongoing Phase 3 SERENITY and TRANQUILITY trials.
BioXcel Therapeutics (Nasdaq: BTAI) announced that its CEO, Vimal Mehta, Ph.D., will present at the Jefferies Global Healthcare Conference on June 5, 2024, in New York City.
The presentation will cover the company's late-stage clinical programs with BXCL501, aimed at treating agitation in Alzheimer's dementia, bipolar disorders, and schizophrenia. Dr. Mehta will be joined by Vincent J. O’Neill, M.D., the Chief of Product Development and Medical Officer.
Investors and stakeholders can access a live webcast and presentation materials via the company's website. The webcast will be available for replay for 90 days.
BioXcel Therapeutics (Nasdaq: BTAI) has announced that Dr. Rob Risinger will present both oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 28 to 31 in Miami Beach, FL. The presentations will focus on the comparison of sublingual Dexmedetomidine with Quetiapine in elderly subjects, a study on BXCL501 with anti-depressants in healthy volunteers, and a dose-finding study of BXCL501 for agitation linked to dementia.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) reported strong financial results for Q1 2024, with plans to advance the TRANQUILITY and SERENITY programs. The company secured two new patents for BXCL501, completed a $25 million offering, and saw a 55% revenue increase. Additionally, the IGALMI™ PMR study and OnkosXcel Therapeutics' abstract presentation were highlighted.
FAQ
What is the current stock price of Bioxcel Therapeutics (BTAI)?
What is the market cap of Bioxcel Therapeutics (BTAI)?
